MATERIALS AND METHODS

Patient population

The database of the Korea University Anam Hospital, Seoul, Korea was searched for all CRC patients who underwent surgical resection between 2002 and 2013. A cohort of patients who underwent hepatic resection or pulmonary resection for CRC metastases was also identified. Patients with available tissue samples were analyzed for MMR using IHC. Patients who received neoadjuvant chemoradiotherapy were excluded. A total of 61 cases were included in the study. The corresponding clinical data were obtained from a retrospective review of patient records. Follow-up survival data were also obtained.

Immunohistochemistry

To characterize the MMR system, IHC was performed using 4-μm-thick paraffin tissue sections. The manufacturers and incubation conditions for primary antibodies are summarized in Table 1. Sections were incubated for 15 minutes with antibodies against MLH1 protein (1:200, ES05, Leica, Newcastle upon Tyne, UK), MSH2 protein (1:100, G219-1129, Cell Marque, Rocklin, CA, USA), MSH6 protein (1:50, 44, Cell Marque), and PMS2 (1:50, MRQ-28, Cell Marque).

Tumors were considered deficient in MLH1, MSH2, MSH6, and PMS2 expression when there was a complete absence of detectable nuclear staining in neoplastic cells. Intact nuclear staining of the adjacent non-neoplastic epithelium, stromal cells, or lymphocytes served as an internal positive control (Appendix 1).

Whole sections were stained and reviewed for cases that showed a loss of expression on a microarray.

Statistical analysis

Clinicopathological features, including age, size, gender, site of primary CRC, lymph node status, lymphovascular invasion, perineural invasion, carcinoembryonic antigen (CEA) levels at diagnosis, T category, tumor differentiation, and metastatic site, were compared between dMMR and proficient MMR (pMMR) patients used Fisher exact, χ² tests and Mann-Whitney test. Overall survival was calculated according to the Kaplan-Meier method. All statistical tests were implemented in SPSS ver. 21 (IBM Corp., Armonk, NY, USA).

This case was reviewed by the Institutional Review Board of Korea University Medical Center (AN15349-00).

RESULTS

Clinicopathological features

The clinicopathological features of 61 patients included in the study are detailed in Table 1. The mean patient age was 58 years (range, 31 to 78 years); 26% of the patients were female and 73% were male. The mean tumor size was 5.4 cm (range, 1.8 to 15 cm). The anatomical location of the primary tumor was classified as left (rectum, rectosigmoid colon, splenic flexure, and descending colon) or right side (ascending colon, hepatic flexure, and cecum). In total, 55/61 (90.1%) were T3 cancers that invade through the muscularis propria into pericolorectal tissues. Moderately differentiated CRCs accounted for 44/61 (72.1%).

There were two patients in their early thirties. Neither patient had a family history of cancer.

Relationship between MMR status and clinicopathological features

Using Fisher exact, χ² tests and Mann-Whitney tests to analyze the relationship between MMR status and clinicopathological features, significant relationships were not detected for age (p=.58), size (p=.14), sex (p=.34), site (p=.96), T stage (p=.36), tumor differentiation (p=.32) lymph node metastasis (p=.13), lymphovascular invasion (p=.75), perineural invasion (p=.30), or CEA level (p=.49).

Association between primary and metastatic tumors

A total of 61 CRCs were assessed using a tissue microarray. The results are detailed in Tables 2 and 3.

Of the primary tumors, 7/61 (11.4%) showed a dMMR system based on IHC, while secondary tumors showed a deficiency in 13/61 cases (21.3%). In total, 44 cases showed proficient expression of MMR in both primary and metastatic lesions. Three cases showed deficiencies in both the primary and the paired metastatic lesions. In 10 cases, proficient expression was found in the primary lesions, but not in the corresponding metastatic lesions. In four cases, proficient expression was detected in the secondary tumor, but not in the primary tumor.

Survival analysis

In total, 14 patients died of cancer, and the median survival was 33 months from the date of initial diagnosis.

A survival analysis was performed assuming that the primary and metastatic tumors showing intact expression using IHC group are pMMR and the loss of expression in either tumor indicates dMMR (Fig. 1). This result was not statistically significant (log-rank test, p=.22), but the pMMR group showed a more favorable prognosis compared to the dMMR group.

DISCUSSION

In this study, MMR proteins were evaluated by IHC for the following reasons: (1) IHC is less time consuming than PCR, (2) is easier to implement [14], and (3) enables the simultaneous identification of affected MMR genes [5].

However, the interpretation of IHC results requires caution for the following reasons. First, it is well known that the IHC staining patterns for MSH6 IHC are variable [8]. Second, stainability is dependent on tissue handling, including fixation and analytical variables. For instance, tissue hypoxia and delayed fixation reduce the sensitivity of detection of MMR gene expression or suppress MMR. Fewer proliferative cells result in lower levels of staining [15]. Third, some MLH1 mutation-positive cases or even cases with MLH1 promoter methylation show false-positive nuclear staining [6,9]. A missense mutation or an in-frame insertion/deletion mutation in MLH1 does not affect MLH1-PMS2 interactions, and thus the protein reacts with the antibody used for IHC. Lastly, interpretation of MMR IHC results requires consideration that the MMR proteins act as heterodimers [6]. For example, CRCs that show loss of MLH1 and PMS2 expression, but intact MSH2 and MSH6 expression indicate an MLH1 deficiency. The loss of PMS2 expression results from MLH1 mutations.

In this study, our major interest was investigating the concordance in MMR deficiencies between the primary CRCs and its corresponding metastases.

Haraldsdottir et al. [16] reported matching IHC results between the primary tumor and metastatic tissue for all cases examined. However, Agoston et al. [17] found discordance in the MMR status between primary tumors and metastases in 20.2% of cases. Haddad et al. [18] found a very low frequency of MSI using PCR in resected CRC hepatic metastases in 190 patients. Unlike in primary CRCs, the rate of MSI in resectable CRC hepatic metastases is approximately 2.5%. Two potential explanations were proposed to explain this discrepancy. First, high-frequency MSI primary CRCs do not frequently metastasize to the liver. Second, high-frequency MSI primary CRCs spread to the liver extensively and therefore are considered unresectable [18]. Previous studies suggest divergent views regarding this issue.

Of the 61 cases, 47 showed concordance in the IHC staining results between the primary and metastatic tumors. The incidence of dMMR was similar to the previously reported incidence of 10%–20% [19]. However, the incidence was somewhat different between the primary (11.5%) and the metastatic (21.3%) cancer groups. In this study, among the 36 hepatic metastatic cancers, five cases showed dMMR in primary CRCs. This frequency of approximately 14% was not as low as that reported in the previous study.

We focused on dMMR cases that showed discordance between primary and metastatic tumors. The clinicopathological features and each MMR protein expressions of the cases with either primary or metastatic dMMR are summarized in Tables 4 and 5. Except one case, 16 cases were T3 cancers. Most of the cases (16/17) presented without perineural invasion. Based on IHC, primary and metastatic lesions of all the cases showed intact MLH1 expression. In 10 cases, proficient expression was found in the primary tumor, but not in the corresponding metastatic lesions. In four cases, proficient expression was detected in the secondary tumor, but not in the primary tumor. Furthermore, the precise MMR proteins that showed a loss of expression were not exactly matched in the primary and the metastatic tumors.

To further examine the data, we divided the dMMR cases into five groups. During heterodimeric complex formation, MMR proteins change concurrently. The loss of PMS2 is followed by the loss of MLH1 expression owing to functional dimerization. Similarly, the loss of MSH2 is accompanied by the loss of MSH6 (Fig. 2). However, the loss of isolated MSH6 or PMS2 is not accompanied by MLH1 or MSH2, reflecting mutations in MSH6 or PMS2 [4]. Although three cases were classified as a combined group that do not belong to the above four groups, most of the dMMR cases fit the classification, indicating that the IHC expression is consistent.

MLH1 mutations are the most common type among the MMR genes. However, the detected loss of the MLH1 protein was significantly less frequent than the loss of the MSH2 protein in this study. As stated above, we attributed this difference to the IHC technique. Most mutations in MSH2 result in truncated proteins, which consequently showed a loss of expression in IHC analyses. However, MLH1 mutations are non-functional missense mutations, and mutated-MLH1 cases also show proficient expression [15]. A meta-analysis showed that using IHC, only 74% of MLH1 losses were detected in the MLH1 mutation-positive cases, compared to the 91% detected using MSI testing. However, MSH2 mutations could be detected in up to 94% of the MSH2 mutation-positive cases by IHC [9]. We infer that there may be false-positive MLH1 cases, and additional PCR studies are needed to identify the precise MLH1 mutations.

In our study, cases were considered deficient if any target locus (e.g., MLH1, MSH2, MSH6, or PMS2) was not expressed. This is a limitation of our study, and variable patterns could lead to erroneous interpretations. Shia et al. [8] analyzed MSH6 using IHC and showed limited staining in the MLH1/PMS2-deficient patients. In one case, we detected the losses of MLH1, MSH6, and PMS2 expression, suggesting a similar scenario.

Some cases showed a loss of MSH2 expression, but intact MSH6 expression. We attributed this discordance in IHC results to the variable reactivity and subjective data interpretations. Further evaluation by PCR is needed to obtain more definitive results.

All cases received adjuvant chemotherapy after resection of the primary tumor, because all cases included in this study were stage IV. Most of the patients (56 cases) were treated with FOLFOX regimens (combination of folic acid, 5-fluorouracil [5-FU] and oxaliplatin). Two cases were treated with leucovorin and 5-FU without oxaliplatin. Three cases were treated only with 5-FU–based chemotherapy. Among the 61 cases, 50 cases received chemotherapy before metastatectomy, wheres 11 cases received chemotherapy after metastatectomy. Of the 50 cases that received chemotherapy before metastatectomy, 11 cases (22%) showed discordance in IHC. In seven cases, proficient expression was found in the primary lesions, but not in the corresponding metastatic lesions. We assume that these losses of expression could be associated with chemotherapy-related effect.

MMR status was not a significant predictive marker in metastatic CRCs. This finding concurs with the results of previous studies [20]. Since all cases were stage IV tumors, the low survival rates were expected.

Despite these limitations, we detected a correlation between the MMR status of primary and metastatic CRCs using only IHC. These findings may improve our understanding of the metastatic processes in CRC patients. Further research should focus on the modifications in the biological and biochemical properties of DNA MMR proteins during metastatic processes.

Fig. 1.

Overall survival for the entire cohort (proficient mismatch repair [MMR] and deficient MMR patients).

Fig. 2.

Immunohistochemical analyses of primary colorectal cancer for MLH1 (A), MSH2 (B), MSH6 (C), and PMS2 (D). Immunohistochemical analyses of metastatic colorectal cancer for MLH1 (E), MSH2 (F), MSH6 (G), and PMS2 (H). A lack of staining for MSH2 and MSH6 indicates a primary defect in MSH2, with a secondary loss of MSH6 expression.

REFERENCES

• 1. Kanthan R, Senger JL, Kanthan SC. Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int 2012; 2012: 597497.ArticlePubMedPMCPDF
• 2. Yim KL. Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome. Med Oncol 2012; 29: 1796-801. ArticlePubMedPDF
• 3. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-6. ArticlePubMed
• 4. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 2011; 135: 1269-77. ArticlePubMedPDF
• 5. Shia J. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol 2015; 32: 352-61. ArticlePubMedPMC
• 6. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer: the stable evidence. Nat Rev Clin Oncol 2010; 7: 153-62. ArticlePubMedPMCPDF
• 7. Chen S, Watson P, Parmigiani G. Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard. Biostatistics 2005; 6: 450-64. ArticlePubMedPMC
• 8. Shia J, Zhang L, Shike M, et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol 2013; 26: 131-8. ArticlePubMedPDF
• 9. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10: 301-7. PubMedPMC
• 10. Shia J, Klimstra DS, Nafa K, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005; 29: 96-104. ArticlePubMed
• 11. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010; 56: 167-79. ArticlePubMed
• 12. Leach FS, Polyak K, Burrell M, et al. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996; 56: 235-40. PubMed
• 13. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996; 56: 4836-40. PubMed
• 14. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043-8. ArticlePubMed
• 15. Shia J, Holck S, Depetris G, Greenson JK, Klimstra DS. Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer 2013; 12: 241-60. ArticlePubMedPDF
• 16. Haraldsdottir S, Roth R, Pearlman R, Hampel H, Arnold CA, Frankel WL. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Fam Cancer 2016; 15: 253-60. ArticlePubMedPDF
• 17. Agoston EI, Baranyai Z, Dede K, et al. Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases. Orv Hetil 2015; 156: 1460-71. PubMed
• 18. Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol 2004; 11: 977-82. ArticlePubMedPDF
• 19. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009; 100: 266-73. ArticlePubMedPMCPDF
• 20. Kim ST, Lee J, Park SH, et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol 2010; 27: 1277-85. ArticlePubMedPDF

Appendix

Appendix 1.

Absence of immunohistochemical staining in tumor epithelium for MLH1 (A), MSH2 (B), MSH6 (C), and PMS2 (D). Note the presence of tumor-infiltrating lymphocytes and adjacent normal mucosal tissue that stain positively for each immunohistochemical staining.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report
  Hailing Yu, Tan Deng, Hongbing Liu
  Human Vaccines & Immunotherapeutics.2025;[Epub]     CrossRef
• Prognostic and Predictive Value of Microsatellite Instability Analysis in Circulating Tumor DNA Using Digital Droplet PCR for Patients With Microsatellite Instability Colorectal Cancers
  Camille Evrard, Tristan Rochelle, Marine Martel, Anis Al Achkar, Aurélie Ferru, Violaine Randrian, Lucie Karayan-Tapon, David Tougeron
  Laboratory Investigation.2025; 105(8): 104176.     CrossRef
• HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series
  Alessandro Vanoli, Tommaso Colella, Paola Parente, Giuseppe De Lisi, Federica Grillo, Erica Quaquarini, Salvatore Corallo, Rondell Patrell Graham, Marc Ferrante, Annick Moens, Gert De Hertogh, Camilla Guerini, Roberta Riboni, Paola Alberizzi, Luca Mastrac
  Modern Pathology.2025; 38(11): 100825.     CrossRef
• Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis
  Dandan Cao, Aiping Zhou
  Current Oncology.2025; 32(9): 493.     CrossRef
• MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice
  Paola Parente, Umberto Malapelle, Valentina Angerilli, Mariangela Balistreri, Sara Lonardi, Salvatore Pucciarelli, Caterina De Luca, Francesco Pepe, Gianluca Russo, Elena Vigliar, Angela Danza, Fabio Scaramuzzi, Giancarlo Troncone, Paolo Graziano, Matteo
  Journal of Clinical Pathology.2023; 76(7): 492.     CrossRef
• Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression
  Jing Zhang, Xin Zhang, Qian Wang, Yu-yin Xu, Qian-lan Yao, Dan Huang, Wei-qi Sheng, Xiao-li Zhu, Xiao-yan Zhou, Qian-ming Bai
  Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3423.     CrossRef
• Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer
  Qianpeng Huang, Tao Yu, Lei Li, Qi Zhang, Shiyao Zhang, Baosong Li, Xiaoping Li, Wanyi Xiao, Gang Liu
  Applied Immunohistochemistry & Molecular Morphology.2023; 31(2): 84.     CrossRef
• Patterns of DNA mismatch repair protein expression for primary and recurrent colorectal cancer at an advanced surgical unit: A retrospective audit
  Charles Risbey, Timothy Fielder, Daniel Steffens, Joo‐Shik Shin, Michael Solomon
  Colorectal Disease.2023; 25(3): 369.     CrossRef
• Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution
  Hyun-Hee Koh, Eunhyang Park, Hyun-Soo Kim
  Biomedicines.2023; 11(8): 2269.     CrossRef
• Multilevel Heterogeneity of Colorectal Cancer Liver Metastasis
  Hao Chen, Chongya Zhai, Xian Xu, Haidong Wang, Weidong Han, Jiaying Shen
  Cancers.2023; 16(1): 59.     CrossRef
• Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers
  Camille Evrard, Stéphane Messina, David Sefrioui, Éric Frouin, Marie-Luce Auriault, Romain Chautard, Aziz Zaanan, Marion Jaffrelot, Christelle De La Fouchardière, Thomas Aparicio, Romain Coriat, Julie Godet, Christine Silvain, Violaine Randrian, Jean-Chri
  International Journal of Molecular Sciences.2022; 23(8): 4427.     CrossRef
• Clinicopathologic Factors Associated with Mismatch Repair Status Among Filipino Patients with Young-Onset Colorectal Cancer
  Dennis Lee Sacdalan, Reynaldo L Garcia, Michele H Diwa, Danielle Benedict Sacdalan
  Cancer Management and Research.2021; Volume 13: 2105.     CrossRef
• Recommendations for Specimen and Therapy Selection in Colorectal Cancer
  Snehal B. Patel, Robert Bookstein, Navid Farahani, Myriam Chevarie-Davis, Andy Pao, Angela Aguiluz, Christian Riley, Jennelle C. Hodge, Serhan Alkan, Zhenqui Liu, Nan Deng, Jean R. Lopategui
  Oncology and Therapy.2021; 9(2): 451.     CrossRef
• Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy
  Elizabeth M. Jacobi, Gene Landon, Russell R. Broaddus, Sinchita Roy-Chowdhuri
  Archives of Pathology & Laboratory Medicine.2021; 145(1): 46.     CrossRef
• Médecine de précision et immunoradiothérapie
  C. Chargari, C. Robert, C. Genestie, E. Deutsch
  Cancer/Radiothérapie.2021; 25(6-7): 570.     CrossRef
• Identificación del fenotipo de inestabilidad microsatelital en carcinoma colorrectal mediante el análisis de la expresión de proteínas reparadoras del ADN: Revisión narrativa
  Orlando Rodas-Pernillo, Edith Oregón
  Ciencia, Tecnologí­a y Salud.2021; 8(2): 232.     CrossRef
• Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition
  Saori Mishima, Hiroya Taniguchi, Kiwamu Akagi, Eishi Baba, Yutaka Fujiwara, Akira Hirasawa, Masafumi Ikeda, Osamu Maeda, Kei Muro, Hiroshi Nishihara, Hiroyki Nishiyama, Tadao Takano, Katsuya Tsuchihara, Yasushi Yatabe, Yasuhiro Kodera, Takayuki Yoshino
  International Journal of Clinical Oncology.2020; 25(2): 217.     CrossRef
• Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment
  James Saller, Dahui Qin, Seth Felder, Domenico Coppola
  Clinical Colorectal Cancer.2020; 19(2): 123.     CrossRef
• Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts
  John J Aird, Michael J Steel, Christine Chow, Julie Ho, Robert Wolber, C Blake Gilks, Lynn N Hoang, David F Schaeffer
  Histopathology.2020; 76(4): 521.     CrossRef
• Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy
  A.  A. Tryakin, M.  Yu. Fedyanin, A.  S. Tsukanov, Yu.  A. Shelygin, I.  A. Pokataev, E.  O. Ignatova, G.  G. Khakimova, M.  A. Frolova, S.  A. Tjulandin
  Malignant tumours.2020; 9(4): 59.     CrossRef
• Spontaneous regression of transverse colon cancer with high-frequency microsatellite instability: a case report and literature review
  Nozomi Karakuchi, Manabu Shimomura, Kazuhiro Toyota, Takao Hinoi, Hideki Yamamoto, Seiji Sadamoto, Koichi Mandai, Hiroyuki Egi, Hideki Ohdan, Tadateru Takahashi
  World Journal of Surgical Oncology.2019;[Epub]     CrossRef
• Biomarker concordance between primary colorectal cancer and its metastases
  D.S. Bhullar, J. Barriuso, S. Mullamitha, M.P. Saunders, S.T. O'Dwyer, O. Aziz
  EBioMedicine.2019; 40: 363.     CrossRef
• Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins
  Amira Jaballah-Gabteni, Haifa Tounsi, Maria Kabbage, Yosr Hamdi, Sahar Elouej, Ines Ben Ayed, Mouna Medhioub, Moufida Mahmoudi, Hamza Dallali, Hamza Yaiche, Nadia Ben Jemii, Afifa Maaloul, Najla Mezghani, Sonia Abdelhak, Lamine Hamzaoui, Mousaddak Azzouz,
  Journal of Translational Medicine.2019;[Epub]     CrossRef
• Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study
  Zheng Wang, Xiaoli Tang, Xiaoqing Wu, Meiyuan Yang, Daorong Wang
  Bioscience Reports.2019;[Epub]     CrossRef
• Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice
  Gaelle Tachon, Eric Frouin, Lucie Karayan-Tapon, Marie-Luce Auriault, Julie Godet, Valerie Moulin, Qing Wang, David Tougeron
  European Journal of Cancer.2018; 95: 112.     CrossRef
• DNA mismatch repair in cancer
  Marina Baretti, Dung T. Le
  Pharmacology & Therapeutics.2018; 189: 45.     CrossRef
• Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors
  Robert M. Ta, Jonathan L. Hecht, Douglas I. Lin
  Gynecologic Oncology.2018; 151(3): 401.     CrossRef
• The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases
  Stacey A. Cohen, Ming Yu, Kelsey Baker, Mary Redman, Chen Wu, Tai J. Heinzerling, Ralph M. Wirtz, Elpida Charalambous, George Pentheroudakis, Vassiliki Kotoula, Konstantine T. Kalogeras, George Fountzilas, William M. Grady
  Clinical Epigenetics.2017;[Epub]     CrossRef